lonaprisan profile

lonaprisan: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	6918548
CHEMBL ID	146032
SCHEMBL ID	977182
MeSH ID	M0560040

Synonym
zk-pra
zk-230211
lonaprisan
CHEMBL146032
bay86-5044
zk 230211
(8s,11r,13s,14s,17s)-11-(4-acetylphenyl)-17-hydroxy-13-methyl-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
211254-73-8
lonaprisan (usan/inn)
D10016
lonaprisan [usan:inn]
zk 232011
zk230211
unii-f5z5el4d26
f5z5el4d26 ,
11-(4-acetylphenyl)-17-hydroxy-17-(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one
bdbm50409115
lonaprisan [usan]
lonaprisan [who-dd]
lonaprisan [inn]
11beta-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17alpha-pregna-5,9-dien-3-one
(8s,11r,13s,14s,17s)-11-(4-acetylphenyl)-17-hydroxy-13-methyl-17-(perfluoroethyl)-6,7,8,11,12,13,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3(2h)-one
SCHEMBL977182
DTXSID60893551
zk 230211; zk 232011
Q27277684
vhzpudnsvgrvmb-rxdlhwjpsa-n

Excerpt	Reference
"Lonaprisan is a novel, type III PR antagonist that was well tolerated in phase I studies."	( Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Bachelot, T; Jonat, W; Kuss, I; Reimann, U; Robertson, JFR; Ruhstaller, T, 2013)

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Progesterone receptor	Homo sapiens (human)	IC50 (µMol)	0.0000	0.0000	0.5807	10.0000	AID147641; AID147645
Glucocorticoid receptor	Mus musculus (house mouse)	IC50 (µMol)	0.0160	0.0022	0.2061	0.6000	AID147644
Androgen receptor	Homo sapiens (human)	IC50 (µMol)	0.0540	0.0000	0.8753	10.0000	AID147642
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
ovulation from ovarian follicle	Progesterone receptor	Homo sapiens (human)
glandular epithelial cell maturation	Progesterone receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Progesterone receptor	Homo sapiens (human)
signal transduction	Progesterone receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Progesterone receptor	Homo sapiens (human)
cell-cell signaling	Progesterone receptor	Homo sapiens (human)
positive regulation of gene expression	Progesterone receptor	Homo sapiens (human)
negative regulation of gene expression	Progesterone receptor	Homo sapiens (human)
paracrine signaling	Progesterone receptor	Homo sapiens (human)
negative regulation of phosphorylation	Progesterone receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Progesterone receptor	Homo sapiens (human)
lung alveolus development	Progesterone receptor	Homo sapiens (human)
regulation of epithelial cell proliferation	Progesterone receptor	Homo sapiens (human)
progesterone receptor signaling pathway	Progesterone receptor	Homo sapiens (human)
maintenance of protein location in nucleus	Progesterone receptor	Homo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesis	Progesterone receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Progesterone receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Progesterone receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
MAPK cascade	Androgen receptor	Homo sapiens (human)
in utero embryonic development	Androgen receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure	Androgen receptor	Homo sapiens (human)
epithelial cell morphogenesis	Androgen receptor	Homo sapiens (human)
transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
signal transduction	Androgen receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Androgen receptor	Homo sapiens (human)
cell-cell signaling	Androgen receptor	Homo sapiens (human)
spermatogenesis	Androgen receptor	Homo sapiens (human)
single fertilization	Androgen receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Androgen receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Androgen receptor	Homo sapiens (human)
positive regulation of gene expression	Androgen receptor	Homo sapiens (human)
male somatic sex determination	Androgen receptor	Homo sapiens (human)
intracellular estrogen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
androgen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
intracellular receptor signaling pathway	Androgen receptor	Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
Leydig cell differentiation	Androgen receptor	Homo sapiens (human)
multicellular organism growth	Androgen receptor	Homo sapiens (human)
positive regulation of phosphorylation	Androgen receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Androgen receptor	Homo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathway	Androgen receptor	Homo sapiens (human)
positive regulation of cell differentiation	Androgen receptor	Homo sapiens (human)
negative regulation of integrin biosynthetic process	Androgen receptor	Homo sapiens (human)
positive regulation of integrin biosynthetic process	Androgen receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Androgen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase III	Androgen receptor	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Androgen receptor	Homo sapiens (human)
regulation of developmental growth	Androgen receptor	Homo sapiens (human)
animal organ formation	Androgen receptor	Homo sapiens (human)
male genitalia morphogenesis	Androgen receptor	Homo sapiens (human)
epithelial cell proliferation	Androgen receptor	Homo sapiens (human)
negative regulation of epithelial cell proliferation	Androgen receptor	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Androgen receptor	Homo sapiens (human)
activation of prostate induction by androgen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
morphogenesis of an epithelial fold	Androgen receptor	Homo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesis	Androgen receptor	Homo sapiens (human)
prostate gland growth	Androgen receptor	Homo sapiens (human)
prostate gland epithelium morphogenesis	Androgen receptor	Homo sapiens (human)
epithelial cell differentiation involved in prostate gland development	Androgen receptor	Homo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesis	Androgen receptor	Homo sapiens (human)
mammary gland alveolus development	Androgen receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland development	Androgen receptor	Homo sapiens (human)
cellular response to steroid hormone stimulus	Androgen receptor	Homo sapiens (human)
cellular response to estrogen stimulus	Androgen receptor	Homo sapiens (human)
cellular response to testosterone stimulus	Androgen receptor	Homo sapiens (human)
seminiferous tubule development	Androgen receptor	Homo sapiens (human)
non-membrane-bounded organelle assembly	Androgen receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Androgen receptor	Homo sapiens (human)
regulation of protein localization to plasma membrane	Androgen receptor	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Androgen receptor	Homo sapiens (human)
male gonad development	Androgen receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Androgen receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Progesterone receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Progesterone receptor	Homo sapiens (human)
transcription coactivator binding	Progesterone receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Progesterone receptor	Homo sapiens (human)
DNA binding	Progesterone receptor	Homo sapiens (human)
nuclear steroid receptor activity	Progesterone receptor	Homo sapiens (human)
G protein-coupled receptor activity	Progesterone receptor	Homo sapiens (human)
steroid binding	Progesterone receptor	Homo sapiens (human)
protein binding	Progesterone receptor	Homo sapiens (human)
zinc ion binding	Progesterone receptor	Homo sapiens (human)
enzyme binding	Progesterone receptor	Homo sapiens (human)
identical protein binding	Progesterone receptor	Homo sapiens (human)
ATPase binding	Progesterone receptor	Homo sapiens (human)
estrogen response element binding	Progesterone receptor	Homo sapiens (human)
nuclear receptor activity	Progesterone receptor	Homo sapiens (human)
transcription cis-regulatory region binding	Androgen receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Androgen receptor	Homo sapiens (human)
RNA polymerase II general transcription initiation factor binding	Androgen receptor	Homo sapiens (human)
transcription coactivator binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Androgen receptor	Homo sapiens (human)
chromatin binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Androgen receptor	Homo sapiens (human)
nuclear receptor activity	Androgen receptor	Homo sapiens (human)
G protein-coupled receptor activity	Androgen receptor	Homo sapiens (human)
signaling receptor binding	Androgen receptor	Homo sapiens (human)
steroid binding	Androgen receptor	Homo sapiens (human)
androgen binding	Androgen receptor	Homo sapiens (human)
protein binding	Androgen receptor	Homo sapiens (human)
beta-catenin binding	Androgen receptor	Homo sapiens (human)
zinc ion binding	Androgen receptor	Homo sapiens (human)
enzyme binding	Androgen receptor	Homo sapiens (human)
ATPase binding	Androgen receptor	Homo sapiens (human)
molecular adaptor activity	Androgen receptor	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Androgen receptor	Homo sapiens (human)
POU domain binding	Androgen receptor	Homo sapiens (human)
molecular condensate scaffold activity	Androgen receptor	Homo sapiens (human)
estrogen response element binding	Androgen receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Progesterone receptor	Homo sapiens (human)
nucleoplasm	Progesterone receptor	Homo sapiens (human)
mitochondrial outer membrane	Progesterone receptor	Homo sapiens (human)
cytosol	Progesterone receptor	Homo sapiens (human)
chromatin	Progesterone receptor	Homo sapiens (human)
nucleus	Progesterone receptor	Homo sapiens (human)
nucleoplasm	Glucocorticoid receptor	Mus musculus (house mouse)
plasma membrane	Androgen receptor	Homo sapiens (human)
nucleus	Androgen receptor	Homo sapiens (human)
nucleoplasm	Androgen receptor	Homo sapiens (human)
cytoplasm	Androgen receptor	Homo sapiens (human)
cytosol	Androgen receptor	Homo sapiens (human)
nuclear speck	Androgen receptor	Homo sapiens (human)
chromatin	Androgen receptor	Homo sapiens (human)
protein-containing complex	Androgen receptor	Homo sapiens (human)
nucleus	Androgen receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay ID	Title	Year	Journal	Article
AID74370	Relative binding affinity against Glucocorticoid receptor of rat after 2 hr incubation as percent binding compared to Dexamethasone	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID147654	In vitro agonist potency in transactivation assay of CV-1 cells stably transfected with human androgen receptor	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID192364	Incomplete abortifacient effect at 0.3 mg/animal/day in pregnant rats	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID181268	Antiglucocorticoid activity in adrenalectomized young male rats after oral administration	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID69529	Relative binding affinity against Estrogen receptor of rat after 2 hr incubation as percent binding compared to estradiol	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID147656	In vitro agonist potency in transactivation assay in NIH3T3 cells expressing glucocorticoid receptor	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID192360	Full abortifacient effect at 0.1 mg/animal/day in pregnant rats	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID192363	Incomplete abortifacient effect at 0.1 mg/animal/day in pregnant rats	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID147644	In vitro antagonist potency in transactivation assay in NIH3T3 cells expressing glucocorticoid receptor	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID147643	In vitro antagonist potency in transactivation assay in MVLN cells expressing estrogen receptor	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID147655	In vitro agonist potency in transactivation assay of MVLN cells expressing estrogen receptor	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID192359	Full abortifacient effect at 0.03 mg/animal/day in pregnant rats	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID181267	Antiandrogenic activity in orchidectomized young male rats after oral administration	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID162452	Relative binding affinity against rabbit progesterone (PR) receptor after 24 hr incubation as perent binding compared to progesterone	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID147645	In vitro antagonist potency in transactivation assay in neuroblastoma cells expressing human PR-B progesterone receptor	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID192362	Incomplete abortifacient effect at 0.03 mg/animal/day in pregnant rats	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID147642	In vitro antagonist potency in transactivation assay in CV-1 cells expressing androgen receptor	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID147641	In vitro antagonist potency in transactivation assay in neuroblastoma cells expressing human PR-A progesterone receptor	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID39309	Relative binding affinity against androgen (AR) receptor of rat after 24 hr incubation as percent binding compared to R1881	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID147653	In vitro agonist potency in transactivation assay of neuroblastoma cells expressing human PR-A progesterone receptor	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID147657	In vitro agonist potency in transactivation assay in neuroblastoma cells expressing human PR-B progesterone receptor	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
AID192361	Full abortifacient effect at 0.3 mg/animal/day in pregnant rats	2000	Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (45.45)	29.6817
2010's	6 (54.55)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (18.18%)	5.53%
Reviews	2 (18.18%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (63.64%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	3.15	1	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
mifepristone Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.	2	1	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
onapristone onapristone: induces vaginal bleeding and luteal regression in monkeys; structure given in first source; progesterone antagonist	2	1
vilaprisan vilaprisan: a progesterone receptor modulator; structure in first source	2.17	1

Condition	Indicated	Relationship Strength	Studies	Trials
Experimental Mammary Neoplasms [description not available]	0	2	1	0
Female Genital Diseases [description not available]	0	2.17	1	0
Fibroid [description not available]	0	2.17	1	0
Genital Diseases, Female Pathological processes involving the female reproductive tract (GENITALIA, FEMALE).	0	2.17	1	0
Leiomyoma A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.	0	2.17	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	2.17	1	0
Breast Cancer [description not available]	0	8.88	7	4
Breast Neoplasms Tumors or cancer of the human BREAST.	1	10.88	7	4
Adult Pelizaeus-Merzbacher Disease [description not available]	0	2.1	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.46	2	0
Adenocarcinoma, Basal Cell [description not available]	0	2.05	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	2.05	1	0
Cancer of the Uterus [description not available]	0	2.97	1	0
Uterine Neoplasms Tumors or cancer of the UTERUS.	0	2.97	1	0
Bleeding Between Periods [description not available]	0	2.03	1	0
Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.	0	2.03	1	0
Metrorrhagia Abnormal uterine bleeding that is not related to MENSTRUATION, usually in females without regular MENSTRUAL CYCLE. The irregular and unpredictable bleeding usually comes from a dysfunctional ENDOMETRIUM.	0	2.03	1	0
Heavy Menstrual Bleeding [description not available]	0	3.42	1	1
Menorrhagia Excessive uterine bleeding during MENSTRUATION.	0	3.42	1	1

lonaprisan

Description

Cross-References

Synonyms (27)

Research Excerpts

Overview

Protein Targets (3)

Inhibition Measurements

Biological Processes (67)

Molecular Functions (26)

Ceullar Components (9)

Bioassays (22)

Research

Studies (11)

Study Types

lonaprisan

Description

Cross-References

Synonyms (27)

Research Excerpts

Overview

Protein Targets (3)

Inhibition Measurements

Biological Processes (67)

Molecular Functions (26)

Ceullar Components (9)

Bioassays (22)

Research

Studies (11)

Study Types

Related Drugs (4)

Related Conditions (19)